Compare Stocks

Date Range: 

 Gemini TherapeuticsSilence TherapeuticsBELLUS HealthPfenexSigilon Therapeutics
SymbolNASDAQ:GMTXLON:SLNTSE:BLUNYSEAMERICAN:PFNXNASDAQ:SGTX
Price Information
Current Price$11.98GBX 628C$4.68$12.75$13.30
52 Week RangeBuyHoldBuyHoldBuy
MarketRank™
Overall Score1.70.70.50.71.4
Analysis Score3.51.00.01.23.4
Community Score5.02.62.42.43.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyHoldBuy
Consensus Price Target$22.00GBX 605N/A$13.67$53.75
% Upside from Price Target83.64% upside-3.66% downsideN/A7.19% upside304.14% upside
Trade Information
Market Cap$515.13 million£561.42 millionC$366.62 million$437.29 million$419.34 million
BetaN/AN/AN/AN/AN/A
Average Volume268,641102,233212,927503,865117,036
Sales & Book Value
Annual RevenueN/A£5.48 millionC$15,000.00N/AN/A
Price / SalesN/A102.4724,441.27N/AN/A
CashflowN/AGBX 45 per shareC$1.25 per shareN/AN/A
Price / CashN/A13.963.73N/AN/A
Book ValueN/AGBX 10.90 per shareC$1.88 per shareN/AN/A
Price / BookN/A0.582.49N/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AGBX (39.80)C($0.66)N/AN/A
Trailing P/E Ratio0.00N/AN/A0.000.00
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A3.76%0.34%N/AN/A
Current RatioN/A2.99%18.11%N/AN/A
Quick RatioN/A2.78%17.57%N/AN/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees2965327199
Shares Outstanding43.00 million89.40 million78.34 million34.30 million31.53 million
Next Earnings DateN/AN/A5/13/2021 (Estimated)N/A6/17/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Sigilon Therapeutics to Present at the BofA Securities 2021 Healthcare ConferenceSigilon Therapeutics to Present at the BofA Securities 2021 Healthcare Conference
finance.yahoo.com - May 6 at 8:41 AM
Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual MeetingSigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting
finance.yahoo.com - April 27 at 7:29 PM
Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Short Interest UpdateSigilon Therapeutics, Inc. (NASDAQ:SGTX) Short Interest Update
americanbankingnews.com - April 14 at 8:26 AM
Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare ConferenceSigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 8 at 7:30 AM
Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic DevelopmentTessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development
finance.yahoo.com - April 7 at 9:29 AM
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business ...Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business ...
apnews.com - March 19 at 8:30 AM
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business HighlightsSigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
finance.yahoo.com - March 19 at 8:30 AM
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business HighlightsSigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
finance.yahoo.com - March 19 at 8:30 AM
Sigilon’s SIG-007 Granted Orphan Drug Designation By FDA; Shares Pop 6%Sigilon’s SIG-007 Granted Orphan Drug Designation By FDA; Shares Pop 6%
finance.yahoo.com - March 8 at 9:50 AM
Sigilon Therapeutics Fabry Disease Therapy Receives Orphan Drug Designation In USSigilon Therapeutics' Fabry Disease Therapy Receives Orphan Drug Designation In US
markets.businessinsider.com - March 7 at 7:26 AM
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry DiseaseSigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
finance.yahoo.com - March 5 at 9:28 AM
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry DiseaseSigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
finance.yahoo.com - March 5 at 9:28 AM
Sigilon Therapeutics to Present at Barclays Global Healthcare ConferenceSigilon Therapeutics to Present at Barclays Global Healthcare Conference
finance.yahoo.com - March 4 at 8:26 AM
Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™
finance.yahoo.com - February 8 at 11:41 AM
Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January ...Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January ...
apnews.com - January 14 at 4:47 AM
Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
finance.yahoo.com - January 13 at 7:36 AM
Sigilon Therapeutics, Inc. (SGTX)Sigilon Therapeutics, Inc. (SGTX)
realmoney.thestreet.com - December 31 at 5:07 AM
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type ISigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
finance.yahoo.com - December 17 at 8:33 AM
Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional SharesSigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
benzinga.com - December 10 at 4:40 PM
Sigilon Therapeutics, Inc. Rings the Closing Bell in Celebration of its IPOSigilon Therapeutics, Inc. Rings the Closing Bell in Celebration of its IPO
nasdaq.com - December 10 at 4:40 PM
Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of ...Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of ...
apnews.com - December 10 at 4:40 PM
Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesSigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - December 10 at 4:40 PM
DateCompanyBrokerageAction
4/14/2021Gemini TherapeuticsSVB LeerinkInitiated Coverage
3/9/2021Gemini TherapeuticsJefferies Financial GroupInitiated Coverage
3/8/2021Gemini TherapeuticsThe Goldman Sachs GroupInitiated Coverage
2/16/2021Gemini TherapeuticsStifel NicolausInitiated Coverage
2/17/2021Silence TherapeuticsPeel HuntReiterated Rating
11/12/2020BELLUS HealthLifesci CapitalReiterated Rating
7/7/2020BELLUS HealthGuggenheimDowngrade
6/26/2020BELLUS HealthHC WainwrightReiterated Rating
8/1/2019BELLUS HealthBloom BurtonReiterated Rating
8/14/2020PfenexCantor FitzgeraldDowngrade
8/14/2020PfenexWilliam BlairDowngrade
8/12/2020PfenexTruist FinancialDowngrade
8/11/2020PfenexJMP SecuritiesDowngrade
6/15/2020PfenexOppenheimerBoost Price Target
5/12/2020PfenexSunTrust BanksLower Price Target
3/7/2019PfenexWedbushReiterated Rating
1/8/2021Sigilon TherapeuticsCanaccord GenuityInitiated Coverage
12/29/2020Sigilon TherapeuticsBarclaysInitiated Coverage
12/29/2020Sigilon TherapeuticsMorgan StanleyInitiated Coverage
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.